display
Mainz (dpa) - The vaccine manufacturer Biontech does not consider a patent release to be expedient, but wants to accommodate poor countries in terms of price.
"We will continue to supply countries with low or lower middle income with our vaccine at a not-for-profit price," the company announced on Saturday in Mainz.
They are convinced that the continuous expansion of production capacities will help to end this pandemic.
"To achieve this, governments, manufacturers as well as international and national organizations must jointly support the supply of low- and low-middle-income countries from existing production facilities and help identify new certified locations."
Patents are "not the limiting factor for the production or supply of our vaccine," said a spokeswoman.
The manufacture of vaccines is a complex process.
If the requirements are not met, the quality, safety and effectiveness of the vaccine could suffer.
A report according to which Biontech temporarily waived patent protection for the corona vaccine is not applicable.
display
A political debate had broken out over patent protection.
The World Health Organization is in favor of generally suspending it in order to be able to supply the population of poorer countries with cheap vaccines.
The US government has followed suit.
Chancellor Angela Merkel has spoken out against it, and the EU does not see it as “a magic bullet”.
© dpa-infocom, dpa: 210508-99-518034 / 2